David Zax hosts IBM’s Mixture of Experts with Kush Varshney, Sridhar Rajagopalan and Alexis Zamkow in this 28-minute discussion.

Mixed chips create a software optimization problem — 0:58

  • Anthropic’s public debut frames a discussion about buying compute across NVIDIA, Amazon and Google.
  • Rajagopalan argues that hardware supply limits push large buyers toward several chip families, each suited to different workloads.
  • Small improvements at the hardware–software boundary can accumulate across a large fleet.
  • Zax’s “hardware ice cream truck” metaphor captures the variety; exploiting those different architectures takes additional software work.
  • Zamkow raises the competing concern: investors supplying compute can concentrate financial and infrastructure power in a small ecosystem.

Agent payments need bounded authority — 10:50

  • The panel discusses ChatGPT Wallet: a person reviews a purchase, approves it, and the agent pays using a substitute card credential.
  • OpenAI’s documentation confirms biometric approval and an initial rollout through dots for eligible US Pro users.
  • Rajagopalan connects short-lived, narrowly scoped credentials to practices used by teams operating large online services.
  • Zax describes a different arrangement: Claude used his logged-in browser to buy a cable after conversational approval.
  • His later $850 projector purchase illustrates another risk: he checked the return policy but had yet to test the product.
  • Varshney invokes the “market for lemons,” where buyers struggle to judge quality and sellers lack information about buyers.
  • Caveat: the panel’s five-minute credential example is not a verified Wallet guarantee; OpenAI says approved recurring plans may permit later merchant charges.

Drug discovery depends on selecting viable molecules — 19:45

  • Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia.
  • Rajagopalan describes computational screening that reduces a huge candidate space before expensive laboratory and human testing.
  • Better candidate selection could improve the odds of later success; the discussion supplies no measured clinical success-rate improvement.
  • Zamkow extends the idea to biomarkers and selecting trial participants, explicitly acknowledging that the hoped-for acceleration remains unproven.
  • Varshney’s Chef Watson analogy separates generating many possibilities from choosing useful ones.
  • Toxicity and solubility matter alongside efficacy: a molecule must be tolerable and practical to administer.
  • Learned predictions from molecular data can guide selection without requiring a complete simulation of the human body.

“The selection part is the hard part.” — Kush Varshney, 25:46